The primary goal of the TCD-REDUCE study is to demonstrate the effectiveness of continuous transcranial Doppler sonography ("sonolysis") on the reduction of the ischemic stroke volume during MitraClip implantation.
Cardiac procedures are associated with new cerebral ischemic lesions detected on diffusion-weighted MRI (Bendszus et al., 2006). A previous study suggests that sonolysis (continuous transcranial Doppler sonography using a 2-MHz diagnostic probe) can reduce the risk of new cerebral ischemic lesions during carotid endarterectomy and carotid angioplasty / stenting (Skoloudik et al., 2015). Currently, it is unknown whether sonolysis can also reduce the risk of new cerebral ischemic lesions during MitraClip implantation - a percutaneous treatment option in patients with moderate / severe mitral regurgitation. In this study, patients will receive cerebral MRI and clinical neurological / neuropsychological examination before and after MitraClip implantation. During MitraClip implantation, all patients will receive continuous transcranial Doppler sonography using a 2-MHz diagnostic probe with maximal diagnostic energy administered through either the left or the right transtemporal window (computer-generated 1:1 randomization). The primary endpoint is the median ischemic lesion volume detected on diffusion-weighted MRI after MitraClip implantation in the sonolysis group and in the control group.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Enrollment
32
Continuous transcranial Doppler sonography (TCD) using a 2-MHz diagnostic probe with maximal diagnostic energy
Charité-Campus Benjamin Franklin
Berlin, Germany
RECRUITINGstroke volume
median volume (in ml) of new ischemic lesions detected on diffusion-weighted MRI after MitraClip implantation in the sonolysis and in the control group
Time frame: 0-5 days after the MitraClip Implantation
diffusion-weighted MRI lesions
new ischemic lesions (occurrence, number and location) detected on diffusion-weighted MRI after MitraClip implantation
Time frame: 0-5 days after the MitraClip Implantation
intracerebral hemorrhage (ICH) and / or subarachnoid hemorrhage (SAH)
new ICH and / or SAH detected on T2\*-weighted MRI after MitraClip implantation
Time frame: 0-5 days after the MitraClip Implantation
cerebral microbleeds (CMB)
new cerebral microbleeds detected on T2\*-weighted MRI after MitraClip implantation (occurrence, number and location)
Time frame: 0-5 days after the MitraClip Implantation
clinically overt stroke
new clinically overt stroke (ischemic or hemorrhagic) or transient ischemic attack (TIA) after MitraClip implantation
Time frame: (1) 0-5 days after the MitraClip Implantation and (2) 3 months after MitraClip implantation
functional outcome
functional outcome will be evaluated using the modified Rankin scale (mRS). The mRS ranges from 0 to 6 with 0 indicating no functional deficit (best score) and 6 indicating deaths (worst score).
Time frame: (1) 0-5 days after the MitraClip Implantation and (2) 3 months after MitraClip implantation
cognitive outcome during hospital stay
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
cognitive outcome will be evaluated using the Montreal Cognitive Assessment (MoCA)
Time frame: 0-5 days after the MitraClip Implantation
cognitive outcome at follow-up
cognitive outcome will be evaluated using the Telephone Interview for Cognitive Status (TICS)
Time frame: 3 months after MitraClip implantation
delirium
delirium will be evaluated using the 3-Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM)
Time frame: 0-5 days after the MitraClip Implantation
length of hospital stay (duration of hospitalization for the MitraClip implantation)
days of hospital stay from admission to hospital to discharge from hospital including direction of discharge (home, another hospital)
Time frame: length of hospital stay (up to 3 months after MitraClip implantation)
mortality
mortality
Time frame: up to 3 months after MitraClip implantation